Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
BeiGene
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Confirmed diagnosis of relapsed or refractory extranodal NK/T-cell lymphoma (nasal or non-nasal type, peripheral T-cell lymphoma - not otherwise specified, angioimmunoblastic T-cell lymphoma, anaplastic large cell lymphoma, mycosis fungoides, or Sezary syndrome)
Age 18 years or older
Relapsed or refractory to at least 1 prior systemic therapy
Measurable disease by computed tomography (CT)/magnetic resonance imaging (MRI) for participants in Cohort 1 and 2
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
Life expectancy ≥ 6 months
Adequate respiratory function
Adequate bone marrow function
Adequate renal and hepatic function
You may not be if
Known central nervous system (CNS) involvement by lymphoma
Previously received immune checkpoint therapy
Prior malignancy within the past 3 years, except for curatively treated basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast, or localized Gleason score 6 or lower prostate cancer
Active autoimmune disease or history of autoimmune diseases that may relapse with some exceptions
Severe or debilitating pulmonary disease
Clinically significant cardiovascular disease
Active fungal, bacterial, and/or viral infection requiring systemic therapy
Known infection with HIV or active viral hepatitis B or C infection
Major surgery within 4 weeks of the first dose of study drug
Pregnant or lactating women
Vaccination with a live vaccine within 35 days prior to the first dose of study drug
Hypersensitivity to tislelizumab
Concurrent participation in another therapeutic clinical trial
